Liver FoxO1 overexpression is positively associated with the degree of liver injury in cirrhotic patients
Preprint
Abstract
Introduction: Chronic liver disease is associated with high mortality. Liver transplantation is the definitive treatment for patients with end-stage liver disease, improving their survival and quality of life. However, chronic rejection of the graft and the imbalance between the demand and the availability of organs limit its applicability. Therefore, finding therapeutic and/or diagnostic alternatives for these patients is a priority. In this context, preclinical studies in rodents have demonstrated that Akt plays a key role in liver dysfunction. Even with all this evidence, the activation status of Akt and its downstream targets in the liver of patients with chronic hepatopathy is still unknown. Hence, the present study aims to determine the activation status of the molecules involved in the Akt signaling pathway in livers of cirrhotic patients. Materials and Methods: In this study, 36 liver tissue samples from a cohort of 27 cirrhotic patients and 9 patients without cirrhosis were included. A total of 10 proteins involved in Akt/mTOR pathway (GSK3β, IGF1R, IRS1, mTOR, p70S6K, IR, PTEN, GSK3α, TSC2, and RPS6) were analyzed using a multiplex immunoassay based on Luminex® technology. Results: Significant differences were found in several Akt/mTOR target proteins between the groups of cirrhotic patients vs. non-cirrhotic: FoxO1 (9.5 vs. 4.4; p p p p p p <0.05). Moreover, the individual influence of FoxO1 on these parameters was confirmed by multiple regression analysis. It was the only enzyme in the Akt signaling pathway identified as a positive independent predictor of increased ASAT and ALAT levels. Conclusion: FoxO1 is overexpressed in the liver of cirrhotic patients after partial hepatectomy. FoxO1 levels are also associated with the degree of liver injury, showing a positive correlation with current biomarkers used in clinical practice to detect liver injury.Keywords
All Related Versions
This publication has 16 references indexed in Scilit:
- The Role of Akt in Chronic Liver Disease and Liver RegenerationSeminars in Liver Disease, 2017
- Akt‐mediated foxo1 inhibition is required for liver regenerationHepatology, 2015
- Dissecting the complement pathway in hepatic injury and regeneration with a novel protective strategyJournal of Experimental Medicine, 2014
- Forkhead box class O transcription factors in liver function and diseaseJournal of Gastroenterology and Hepatology, 2013
- Akt, FoxO and regulation of apoptosisBiochimica et Biophysica Acta (BBA) - Molecular Cell Research, 2011
- The survival pathways phosphatidylinositol‐3 kinase (PI3‐K)/phosphoinositide‐dependent protein kinase 1 (PDK1)/Akt modulate liver regeneration through hepatocyte size rather than proliferation†Hepatology, 2008
- Gene Transduction of an Active Mutant of Akt Exerts Cytoprotection and Reduces Graft Injury After Liver TransplantationAmerican Journal of Transplantation, 2007
- A crucial role for GRK2 in regulation of endothelial cell nitric oxide synthase function in portal hypertensionNature Medicine, 2005
- Transduction of the liver with activated Akt normalizes portal pressure in cirrhotic ratsGastroenterology, 2003
- Rapid Activation of Protein Kinase B/Akt Has a Key Role in Antiapoptotic Signaling during Liver RegenerationBiochemical and Biophysical Research Communications, 2000